Sindhu Sardar, Koshy Merin, Al-Roub Areej Abu, Akhter Nadeem, Al Zanki Saad, Ali Shamsha, Devarajan Sriraman, Ahmad Rasheed
Immunology & Innovative Cell Therapy Unit, P.O. Box 1180, Dasman, 15462 Kuwait.
Tissue Bank Facility, Dasman Diabetes Institute (DDI), P.O. Box 1180, Dasman, 15462 Kuwait.
J Diabetes Metab Disord. 2016 Sep 29;15:40. doi: 10.1186/s40200-016-0264-4. eCollection 2015.
Chronic inflammation is a hallmark of type-2 diabetes (T2D) and asthma. Monocyte chemoattractant protein (MCP)-1 or CCL-2 is a key regulator of monocytic infiltration into the sites of inflammation. The changes in systemic MCP-1 levels and its relationship with other inflammatory/immune markers in T2D patients with asthma remain unclear and have been addressed in this study.
Plasma samples from 10 asthmatic T2D patients (Group I: BMI = 37.82 ± 9.75 kg/m), 13 non-asthmatic T2D patients (Group II: BMI = 32.68 ± 4.63 kg/m), 23 asthma patients without T2D (Group III: BMI = 30.14 ± 6.74 kg/m), and 25 non-asthmatic non-diabetic controls (Group IV: BMI = 27.99 ± 5.86 kg/m) were used to measure levels of MCP-1 and multiple cytokine/chemokine biomarkers with bead-based multiplex assays using Luminex technology. IgE/ECP were measured using commercial ELISA kits. Data (mean ± SEM) were compared using unpaired Student's -test and linear dependence between two variables was assessed by Pearson's correlation coefficient (r) and ≤ 0.05 was considered as significant.
Plasma MCP-1 levels were significantly higher in Group I (337.95 ± 46.40 pg/mL) as compared with Group II (216.69 ± 17.30 pg/mL), Group III (251.76 ± 19.80 pg/mL), and Group IV (223.52 ± 133.36 pg/mL). MCP-1 showed differential association with tested biomarkers by correlating positively with: (i) IFN-α2, IL-10, fractalkine, and VEGF in T2D patients with asthma; (ii) IL-6 and GRO-α in T2D patients without asthma; (iii) MDC, IP-10, GM-CSF, FGF-2, and PDGF-AA/BB in patients with asthma only; and (iv) FPG and TG in non-asthmatic non-diabetic controls. MCP-1 associated with IL-1RA only in subjects with asthma.
The systemic MCP-1 levels were significantly elevated in T2D patients with asthma as compared with those without asthma and/or diabetes while these changes correlated differentially with important biomarkers of inflammation and airway remodeling.
慢性炎症是2型糖尿病(T2D)和哮喘的一个标志。单核细胞趋化蛋白(MCP)-1或CCL-2是单核细胞浸润到炎症部位的关键调节因子。T2D合并哮喘患者全身MCP-1水平的变化及其与其他炎症/免疫标志物的关系仍不清楚,本研究对此进行了探讨。
收集10例哮喘合并T2D患者(I组:BMI = 37.82±9.75kg/m)、13例非哮喘T2D患者(II组:BMI = 32.68±4.63kg/m)、23例无T2D的哮喘患者(III组:BMI = 30.14±6.74kg/m)和25例非哮喘非糖尿病对照者(IV组:BMI = 27.99±5.86kg/m)的血浆样本,采用基于Luminex技术的磁珠多重分析法检测MCP-1和多种细胞因子/趋化因子生物标志物的水平。使用商用ELISA试剂盒检测IgE/ECP。数据(均值±SEM)采用非配对学生t检验进行比较,两个变量之间的线性相关性通过Pearson相关系数(r)进行评估,r≤0.05被认为具有统计学意义。
与II组(216.69±17.30pg/mL)、III组(251.76±19.80pg/mL)和IV组(223.52±133.36pg/mL)相比,I组血浆MCP-1水平显著升高(337.95±46.40pg/mL)。MCP-1与所检测的生物标志物存在差异相关性,在哮喘合并T2D患者中与以下指标呈正相关:(i)IFN-α2、IL-10、fractalkine和VEGF;(ii)在无哮喘的T2D患者中与IL-6和GRO-α;(iii)仅在哮喘患者中与MDC、IP-10、GM-CSF、FGF-2和PDGF-AA/BB;(iv)在非哮喘非糖尿病对照者中与FPG和TG。MCP-1仅在哮喘患者中与IL-1RA相关。
与无哮喘和/或糖尿病的患者相比,哮喘合并T2D患者的全身MCP-1水平显著升高,且这些变化与炎症和气道重塑的重要生物标志物存在差异相关性。